Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

Genasense Plus Temodar(R) and Abraxane(R) Show Promising Early Clinical

Activity

BERKELEY HEIGHTS, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced the presentation of clinical data using the Company's lead oncology drug, Genasense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; Abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid translation of preclinical results that demonstrated marked anticancer synergy with this drug combination. The results will be presented by Dr. Anna C. Pavlick, New York University School of Medicine, at the Chemotherapy Foundation Symposium XXV, entitled "Innovative Cancer Therapy for Tomorrow", at the Marriott Hotel, New York, NY on November 9, 2007.

To date, 8 patients have been accrued to this trial. Of the first 7 evaluable patients, 5 patients have demonstrated clinical benefit, including 3 partial responses that occurred after the first treatment cycle, which have lasted for 40, 24 and 16 weeks, respectively. Two other patients have maintained stable disease lasting for a minimum of 24 weeks. Two patients had progressive disease, and one patient is too early to evaluate. There have been no episodes of Grade 4 (i.e., life-threatening) side-effects. Four patients experienced Grade 3 leukopenia (i.e., reduction in white blood cell count), and 1 patient had Grade 3 thrombocytopenia (i.e., reduction in platelet count).

"Our goal with this trial is to evaluate the synergy of Genasense with drugs other t
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
(Date:8/27/2014)... 2014 Rhythm, a biopharmaceutical company developing peptide ... result in metabolic disorders, announced today that it has ... U.S. Securities and Exchange Commission (SEC) relating to the ... stock. The number of shares to be offered and ... been determined. Citigroup and Cowen and Company ...
(Date:8/27/2014)... how plants survive impact by the huge amounts ... using this energy for photosynthesis. The hypothesis is ... quickly dissipate the energy throughout the entire protein ... Physics have now managed to successfully ,film, this ... light-absorbing proteins which play a role in photosynthesis ...
Breaking Biology Technology:Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2DTU researchers film protein quake for the first time 2
... Mass., March 2, 2011 – EMD Serono, Inc., ... today that it received a complete response letter ... (FDA) on the new drug application (NDA) for ... of cladribine, as a therapy for relapsing-remitting multiple ...
... that could be mistaken for packing material has the ... Professor Lei Zhai and postdoctoral associate Jianhua Zou have ... way that it could be used to detect pollutants ... energy more efficiently. The new material belongs to ...
... Life Technologies Corporation (Nasdaq: LIFE ) ... investors as part of the UBS West Coast Life ... at the company,s headquarters in Carlsbad on Monday, March ... President and Chief Operating Officer, will present on behalf ...
Cached Biology Technology:EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 3EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 4New 'frozen smoke' may improve robotic surgery, energy storage 2Life Technologies to Webcast Investor Presentation as Part of the UBS West Coast Life Sciences & Diagnostics Bus Trip 2
(Date:8/28/2014)... Invasives is now available from the Lady Bird Johnson ... for identifying harmful non-native plant, insect and other invasive ... States cause about $137 billion in economic and other ... kill native plants and more. , "By having streamlined ... invasive species occur, we,re more likely to catch these ...
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2
... to Open 75+ Centers and Expects to Process More ... Background Checks, STAMFORD, Conn., Oct. 29 L-1 ... of identity solutions and,services, was selected by the State ... contract estimated at up to $250 million to provide ...
... sensitive detector technology capable of distinguishing hundreds of ... mimics the way animals recognize odors, researchers at ... have created a new approach for electronic noses. ... is more adept than conventional methodologies at recognizing ...
... 29, 2008 Whether it,s in the human body or ... techniques. Physicians and geologists will be meeting at the ... in common. Through a partnership between UH, ... biomedical and seismic imaging will gather to explore the potential ...
Cached Biology News:L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 2L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 3L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 4Sniffing out a better chemical sensor 2Similarities in imaging the human body, Earth's crust focus of conference at UH 2
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... is used as an internal standard for ... dilution mass spectrometry. 5-OxoETE is a polyunsaturated ... 5-HETE in human neutrophils. It stimulates cytosolic ... of 2 nM. 5-OxoETE selectively stimulates the ...
... of ten double-stranded RNAs, 10, 20, 30, ... 1,000 base pairs. The dsRNA Marker is ... of double-stranded RNAs. A twenty bp RNA ... adjusted to approximately 25 ng/µl in concentration. ...
Biology Products: